July 18, 2018
BONESUPPORT appoints Michael Diefenbeck as Head of Research & Development, Medical and Clinical Affairs
Lund, Sweden, 18:30 CET, 18 July 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, announces that Michael Diefenbeck MD PhD, BONE...
Read more
Read more
July 18, 2018
Cash position and activity update for H1 2018 and key perspectives for the end of 2018
Solid cash position of €13.5 million at June 30, 2018
Key highlights of H1 2018: primary objective met in the first results of TARGET PHASE II study and with...
Read more
Read more
July 13, 2018
HealthCap makes 112th investment as Swedish company Modus Therapeutics completes SEK 140 million financing led by HealthCap
Funds to be used to continue the clinical development of sevuparin for sickle cell disease
STOCKHOLM, SWEDEN – 13 July 2018: Modus Therapeutics AB, a company developing innovati...
Read more
Read more
July 12, 2018
Altimmune Restructures Financing Agreement with Majority of the Remaining Series B Investors
GAITHERSBURG, Md., July 12, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today ...
Read more
Read more
July 12, 2018
Targovax and SOTIO announce first patient dosed in Phase I/II combination trial of ONCOS-102 with DCVAC
Oslo, Norway, 12 July 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing and commercializing immune activators to target hard to treat solid tumors, an...
Read more
Read more
July 12, 2018
New Preclinical Results on Onxeo’s AsiDNA™, First-in-Class DNA Repair Inhibitor, Point to Strong Synergy and Reversion of Tumor Resistance when combined to PARP inhibitors
AsiDNA™ combined with olaparib* more than doubled the complete response rate observed with olaparib alone in an in vivo model of triple negative breast cancer resistant to PA...
Read more
Read more
July 12, 2018
Interim Report Q2 2018
Zubsolv® continues its strong performance
Q2 2018 highlights
Total net revenues of SEK 199.7 million (159.1), up 25.5 percent from Q2 previous year
Zubsolv US net reven...
Read more
Read more
July 11, 2018
Altimmune Appoints Mitchel Sayare as Executive Chairman of the Board, and Adds José Ochoa to Its Leadership Team as Chief Business Officer
GAITHERSBURG, Md., July 10, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on infectious disease, today announced it has...
Read more
Read more
July 5, 2018
Håkan Johansson to start as BONESUPPORT’s CFO at the end of 2018
Lund, Sweden, 18:00 CET, July 4 2018 – BONESUPPORT™ an emerging leader in Orthobiologics for the management of bone voids, announces changes in its leadership team that a...
Read more
Read more
July 3, 2018
Vicore Pharma and HealthCap create a leading drug development company focused on severe lung diseases
July 3, 2018
Vicore Pharma Holding AB (publ) ("Vicore" or "The Company") has entered into an agreement to acquire INIM Pharma AB ("INIM"), a Swedish biopharmaceutical company deve...
Read more
Read more